TRCT
TARS icon

Tower Research Capital (TRC)’s Tarsus Pharmaceuticals TARS Stock Holding History

Tower Research Capital (TRC)’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.4K Sell
1,452
-2,341
-62% -$150K ﹤0.01% 2259
2026
Q1 		$266K Buy
3,793
+871
+30% +$60.9K 0.01% 1398
2025
Q4 		$239K Buy
2,922
+2,402
+462% +$179K 0.01% 1305
2025
Q3 		$30.9K Sell
520
-3,525
-87% -$174K ﹤0.01% 2910
2025
Q2 		$164K Buy
4,045
+2,782
+220% +$125K ﹤0.01% 1969
2025
Q1 		$64.9K Buy
1,263
+759
+151% +$37.5K ﹤0.01% 2037
2024
Q4 		$27.9K Buy
504
+19
+4% +$863 ﹤0.01% 2944
2024
Q3 		$16K Sell
485
-5,359
-92% -$151K ﹤0.01% 3388
2024
Q2 		$159K Buy
5,844
+5,502
+1,609% +$185K ﹤0.01% 2247
2024
Q1 		$12.4K Sell
342
-4,218
-93% -$124K ﹤0.01% 3482
2023
Q4 		$92.3K Buy
4,560
+824
+22% +$13.8K ﹤0.01% 2708
2023
Q3 		$66.4K Buy
3,736
+2,825
+310% +$50K ﹤0.01% 2313
2023
Q2 		$16.5K Buy
911
+42
+5% +$668 ﹤0.01% 3560
2023
Q1 		$11K Buy
869
+127
+17% +$1.86K ﹤0.01% 4268
2022
Q4 		$11K Sell
742
-748
-50% -$12.4K ﹤0.01% 3870
2022
Q3 		$26K Sell
1,490
-1,141
-43% -$18.1K ﹤0.01% 3728
2022
Q2 		$38K Sell
2,631
-3,793
-59% -$56.9K ﹤0.01% 3149
2022
Q1 		$108K Buy
6,424
+5,772
+885% +$107K ﹤0.01% 2147
2021
Q4 		$14K Buy
652
+187
+40% +$4.86K ﹤0.01% 4105
2021
Q3 		$10K Sell
465
-708
-60% -$17.5K ﹤0.01% 4336
2021
Q2 		$34K Buy
1,173
+806
+220% +$25.2K ﹤0.01% 3361
2021
Q1 		$12K Sell
367
-278
-43% -$10.3K ﹤0.01% 4277
2020
Q4 		$27K Buy
+645
New +$18.4K ﹤0.01% 3667

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tower Research Capital (TRC)'s TARS Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Tarsus Pharmaceuticals (TARS) stake by 62% in Q2 2026, selling an estimated $150K and leaving 1,452 shares worth $91.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2259.

Tower Research Capital (TRC) first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $266K in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Tower Research Capital (TRC) held 1,452 shares of Tarsus Pharmaceuticals worth $91.4K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,341 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $150K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2259 holding.
  • Tower Research Capital (TRC) first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Tarsus Pharmaceuticals position peaked at $266K in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.